ClinicalTrials.gg
RecruitingNCT07587242SAFARI44Updated Nov 10, 2026

A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping

A Phase 3 interventional study of AOC 1044 and Placebo in Muscular Dystrophies, Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy) and Muscular Disorders, Atrophic, sponsored by Avidity Biosciences, Inc.. Recruiting at 20 sites in 10 countries. Open to male participants aged 7 Years to 16 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Primary conditionMyotonic DystrophyRegistry: Muscular DystrophiesReclassifiedWhy we changed it
Registry
Muscular Dystrophies — the first condition term the registry derived for this study.
ClinicalTrials.gg
Myotonic Dystrophy
Why
  1. The study's listed conditions name Myotonic Dystrophy, a narrower term within Muscular Dystrophies.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Avidity Biosciences, Inc. (part of Novartis) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 10, 2026First sites in 4 new countries5 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
7 Years to 16 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Myotonic Dystrophy with a site in Italy — 11 open to participants now, 13 under way, 5 of them phase 3. Myotonic Dystrophy · Italy.

Planned enrollment
9th of 11
70 · median 150
Started
2026
with 1 other
Phase 3
6 of 19
5 open now
Primary completion
2029-05
later than 10 of 12 live
Registered
19th of 19
by date
Lead sponsor
3 of 19
Avidity Biosciences, Inc.

Among the 19 studies in Myotonic Dystrophy with a site in Italy, this one is the 9th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2026, is one of 6 in phase 3, reaches primary completion later than 10 of the 12 other live ones, and was the 19th registered.

Myotonic Dystrophy

126 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.

Browse Myotonic Dystrophy studies →

Open to participants now

11 of the 19 studies in Myotonic Dystrophy with a site in Italy are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 35 Myotonic Dystrophy studies recruiting now, 15 (43%) set no upper age limit and 18 (51%) stop at 75 or younger; 22 take children under 18; 8 take healthy volunteers.

This study: 7 Years to 16 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Myotonic Dystrophy with a site in Italy, or all of them as a file.
02

Study summary

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1044 for the treatment of Duchenne Muscular Dystrophy (DMD) with Gene Mutations Amenable to Exon 44 Skipping

Read the detailed description

The study consists of a Screening Period of up to 44 Days, a Randomized 54 Week Treatment Period, a 54 Week Open Label Extension (OLE), and a Follow-Up Period of 6 weeks. Participants will be randomized to receive an intravenous infusion of either delpacibart-zotadirsen or placebo at the clinical study site every 6 weeks for a total of 9 doses. After completion of the randomized treatment period, all participants may enter the OLE portion of the study consisting of 9 doses of AOC 1044 regardless of group assignment in the randomized period. The final dose will occur at Week 102, followed by a final assessment at Week 108 and a safety follow-up visit at Week 114. An Independent Data Monitoring Committee (IDMC) comprising members independent and external to the Sponsor will review safety, tolerability, and efficacy (as needed) data of this study at regular intervals.

03

Conditions studied

  • Muscular Dystrophies
  • Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy)
  • Muscular Disorders, Atrophic
  • Muscular Disease
  • Musculoskeletal Diseases
  • Neuromuscular Diseases (NMD)
  • Nervous System Diseases
  • Genetic Diseases
  • X-Linked
  • Hereditary
  • Neonatal Disease
  • Duchene Muscular Dystrophy
  • Congenital
  • DMD

Keywords

  • AOC
  • AOC 1044
  • AOC 1044-CS3
  • AOC 1044-CS1
  • AOC 1044-CS2
  • EXPLORE44
  • EXPLORE44-OLE
  • SAFARI
  • SAFARI44
  • SAFARI 44
  • Avidity
  • Avidity Biosciences
  • Exon Skipping Therapy
  • Avidity Biosciences Inc., A Novartis Company
  • del-zota
  • DMD
04

In context

Myotonic Dystrophy Reclassified

126 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.

This study's planned enrollment of 70 is above the median of 40 across 67 interventional studies indexed under Myotonic Dystrophy.

Browse Myotonic Dystrophy studies →

Lead sponsor

Avidity Biosciences, Inc. is the lead sponsor of 11 studies on the registry; 4 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

First submitted after Avidity Biosciences, Inc. became part of Novartis.

Compared within Myotonic Dystrophy, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Muscular Dystrophies. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
7 Years to 16 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Ambulatory males with clinical and genetic diagnosis of DMD
  • Acceptable genetic test confirming dystrophin gene mutation amenable to exon 44 skipping
  • 7 to 16 years of age at time of consent
  • TTR and NSAA assessment completed within the protocol specified parameters at Screening
  • On a stable regimen of (including Vamolorone) for at least 6 months prior to Day 1. Steroid regimen must be anticipated to remain stable.

Key Exclusion Criteria:

  • Previous treatment cell or gene therapy.
  • Treatment with another oligonucleotide within 6 months of (not including COVID-19 RNA vaccines).
  • Lab values outside of the protocol specified range at Screening
  • If on any of the following treatments (growth hormone, testosterone or givinostat), participants must be on a stable regimen and must plan to maintain it for the duration of the study. Participants will be excluded if regimen stability prior to informed consent is as follows:
  • Less than 1 month, for growth hormone and/or testosterone
  • Less than 6 months for givinostat
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    AOC 1044

    Participants will receive AOC 1044 intravenously (IV) every 6 weeks (Q6W) during the 54-week double-blind treatment period, followed by a 54-week open-label treatment period in which the same participants will continue to receive AOC 1044 IV Q6W

    Drug: AOC 1044

  • Placebo comparator
    Placebo

    Participants will receive placebo (saline) IV Q6W during the 54-week double-blind treatment period, followed by a 54-week open-label treatment period in which all participants will then receive AOC 1044 IV Q6W

    Drug: Placebo

Interventions

  • AOC 1044 will be administered by intravenous (IV) infusion

  • DrugPlacebo

    Placebo will be administered by intravenous (IV) infusion

07

What researchers measure

Primary outcomes

  1. Change from Baseline in Time to Rise (TTR) Velocity at Week 54

    Time frame: Baseline, Week 54

Secondary outcomes

  1. Change from Baseline in Creatine Kinase (CK) at Week 54

    Time frame: Baseline, Week 54

  2. Change from Baseline in 4-Stair Climb (4SC) Velocity at Week 54

    Time frame: Baseline, Week 54

  3. Change from Baseline in 10-Meter Walk/Run Test (10MWRT) Velocity at Week 54

    Time frame: Baseline, Week 54

  4. Change from Baseline in Stride Velocity 95th Centile (SV95C) at Week 54

    Time frame: Baseline, Week 54

  5. Change from Baseline in North Star Ambulatory Assessment (NSAA) Total Score at Week 54

    Time frame: Baseline, Week 54

  6. Change from Baseline in DMD Quality of Life (DMD-QoL) Score at Week 54

    Time frame: Baseline, Week 54

  7. Change from Baseline in Patient Global Impression of Severity (PGI-S) at Week 54

    Time frame: Baseline, Week 54

  8. Change from Baseline in Caregiver Global Impression of Severity (CaGI-S) at Week 54

    Time frame: Baseline, Week 54

  9. Patient Global Impression of Change (PGI-C) at Week 54

    Time frame: Week 54

  10. Caregiver Global Impression of Change (CaGI-C) at Week 54

    Caregiver Global Impression of Change (CaGI-C) at Week 54

    Time frame: Week 54

  11. Change from Baseline in Quantitative Muscle Testing (QMT) at Week 54

    Time frame: Baseline, Week 54

08

Study locations

20 of 20 sites recruiting
09

References and documents

Related links

Individual participant data

Plan to share: Undecided

10

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2026 (actual). Primary completion is estimated for May 2029, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2026
First posted
May 14, 2026
StartActual
Sep 1, 2026
Primary completionEst.
May 2029
CompletionEst.
Jul 2030
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added — first sites in Netherlands, Australia, Canada and Poland
Show 5 added (1 Italy, 1 Netherlands, 1 Australia, 1 Canada, 1 Poland)
  • IRCCS Ospedale San Raffaele · Milan, Italy
  • Academisch Ziekenhuis Leiden · Leiden, Netherlands
  • The Children's Hospital at Westmead · Westmead, Australia
  • London Health Sciences Centre - Victoria Hospital · London, Canada
  • Uniwersyteckie Centrum Kliniczne, Gdańsk · Gdansk, Poland
across 3 updates, Sep 29, 2026 – Nov 10, 2026
Show all 3 updates
  1. Nov 10, 2026
    2 sites added — first sites in Canada and Poland
    Show 2 added (1 Canada, 1 Poland)
    • London Health Sciences Centre - Victoria Hospital · London, Canada
    • Uniwersyteckie Centrum Kliniczne, Gdańsk · Gdansk, Poland
    + 1 other change: verification date
  2. Oct 13, 2026
    1 site added — first site in Australia
    Show site
    • The Children's Hospital at Westmead · Westmead, Australia
  3. Sep 29, 2026
    2 sites added — first site in Netherlands
    Show 2 added (1 Italy, 1 Netherlands)
    • IRCCS Ospedale San Raffaele · Milan, Italy
    • Academisch Ziekenhuis Leiden · Leiden, Netherlands

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07587242
Responsible party
Sponsor
First posted
May 14, 2026
Start date
Sep 1, 2026
Primary completion
May 2029 (estimated)
Completion
Jul 2030 (estimated)
Last update
Nov 10, 2026

Study contacts

Avidity Bioscience, Inc., A Novartis Company
Contact
Novartis.email@novartis.com
1-888-669-6682

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Delpacibart zotadirsen

Start the discussion